Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02935153 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02937103 | A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies |
| unknown |
| Phase 1 / Phase 2 |
| 45 |
| Southwest Hospital, ChinaOTHER |
| 1 |
| Jun 25, 2019 |
| clinicaltrials |
| NCT02958410 | A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03971565 | Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic Leukemia(LLC) | unknown | — | 47 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT03799224 | Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia | unknown | Phase 2 / Phase 3 | 55 | Peking University People's HospitalOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT02965092 | CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 80 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03366350 | Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 50 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT00503256 | Genetic Study of Chronic Lymphocytic Leukemia Families | unknown | — | 4,000 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2019 | clinicaltrials |
| NCT03588598 | Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | unknown | Phase 1 | 40 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03920813 | Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy | unknown | Phase 4 | 500 | Shandong UniversityOTHER | 0 | Apr 23, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02123836 | Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | unknown | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02310243 | Study of Palbociclib in MLL-rearranged Acute Leukemias | unknown | Phase 1 / Phase 2 | 50 | University of UlmOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02670564 | ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) | unknown | Phase 4 | 1,000 | Swiss Pediatric Oncology GroupOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02861209 | Collaborative Network to Take Responsibility for Oral Anticancer Therapy(CONTACT) | unknown | N/A | 228 | KU LeuvenOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03902197 | CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients | unknown | Phase 2 | 50 | Xuanwu Hospital, BeijingOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03902769 | Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients.(AML) | unknown | N/A | 160 | Rambam Health Care CampusOTHER | 0 | Apr 8, 2019 | clinicaltrials |
| NCT03889951 | Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy | unknown | — | 50 | Assiut UniversityOTHER | 0 | Mar 26, 2019 | clinicaltrials |
| NCT03075969 | Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia | unknown | — | 337 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 9 | Mar 21, 2019 | clinicaltrials |
| NCT03364257 | iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patients(IDENTIFY) | unknown | — | 97 | PathoquestINDUSTRY | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03881774 | Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies | unknown | Phase 1 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03881592 | Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness(GO-CLLEAR) | unknown | — | 400 | Brno University HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02344966 | Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia | unknown | — | 1,100 | Yonsei UniversityOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT03348033 | Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT03599375 | Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | jiuwei cuiOTHER | 0 | Feb 26, 2019 | clinicaltrials |
| NCT03854994 | CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 10 | Yan'an Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02799550 | Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL | unknown | Phase 1 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT01240525 | Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers(ProT4) | unknown | Phase 2 | 114 | University College, LondonOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03000335 | Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk | unknown | — | 65 | Curewize Health Ltd.INDUSTRY | 1 | Feb 4, 2019 | clinicaltrials |
| NCT03825731 | A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | unknown | Early Phase 1 | 20 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT03796390 | Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia | unknown | Phase 1 | 15 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03312205 | CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
| NCT03757000 | A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies | unknown | Phase 1 | 42 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 10, 2018 | clinicaltrials |
| NCT03685786 | CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT | unknown | Phase 1 | 20 | Shenzhen Second People's HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02537977 | CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy | unknown | Phase 1 / Phase 2 | 60 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03366324 | Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | unknown | Phase 1 / Phase 2 | 20 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT02542124 | NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | unknown | Phase 2 | 10 | Neumedicines Inc.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03743909 | Expression of Aberrant CD Markers in Acute Leukemia:Retrospective Study in South Egypt Cancer Institute | unknown | — | 100 | Assiut UniversityOTHER | 0 | Nov 16, 2018 | clinicaltrials |
| NCT03454984 | SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation | unknown | Phase 2 | 40 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00439920 | GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL. | unknown | Phase 2 | — | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Oct 23, 2018 | clinicaltrials |
| NCT03715621 | Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT | unknown | — | 500 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT02717884 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)(TRANSATRA) | unknown | Phase 1 / Phase 2 | 60 | Michael LuebbertOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT02933333 | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor | unknown | Phase 4 | 405 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03665480 | The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03701217 | Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML | unknown | Phase 2 / Phase 3 | 220 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03671460 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 | 18 | Tianjin Mycure Medical Technology Co., LtdINDUSTRY | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03659084 | Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation(GREFFE) | unknown | — | 150 | Hospices Civils de LyonOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT03655145 | HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation(MacHaploMud) | unknown | Phase 3 | 344 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 31, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Jun 25, 2019source: clinicaltrials